Sulforaphane for Liver Health

Verdict: Promising mechanism, but weak human liver evidence

Sulforaphane (from broccoli sprout extract) has a plausible liver-protective mechanism and one small trial showing lower liver enzymes, but there is no evidence it improves actual liver disease, so the case for using it as a liver supplement is weak.

C 🟠 C Weak Evidence Published

🔬Why this grade7-layer evidence engine

This earns a C (Weak Evidence) grade because the supportive human data is thin and limited to surrogate markers. The mechanism is well established: sulforaphane activates the NRF2-KEAP1 pathway, boosting glutathione and phase II detoxification enzymes that reduce hepatic oxidative stress (PMID 29242678). But mechanism alone does not prove clinical benefit.

The most direct human evidence is a single small trial in 52 Japanese men with mildly elevated liver enzymes (PMID 26604653), where 8 weeks of broccoli sprout extract significantly lowered ALT and gamma-GTP versus placebo. It was short, single-population, partly industry-funded, and measured only blood markers, not liver health itself. A Qidong trial in aflatoxin-exposed adults (PMID 16284385) found no overall difference in a liver-carcinogen DNA marker, and a 2025 prediabetes trial (PMID 39929977) missed its primary glucose endpoint and reported no liver outcomes at all.

Crucially, no study tests hard endpoints like NAFLD/NASH histology, fibrosis, or liver-cancer and mortality rates. Regulators and clinics reinforce caution: the FDA has not approved or evaluated it for any disease, EFSA leaves such botanical claims unauthorized, and Mayo, Cleveland Clinic, and Harvard emphasize weight loss, alcohol reduction, and treating root causes over supplements, noting some supplements can themselves harm the liver. Falling liver enzymes are not proof of a healthier liver.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.45
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published
Confidence
60%
Broadly consistent
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.40
L5 Clinical bodiesAuthoritative stance
0.40
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.445
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Sulforaphane-rich broccoli sprout extract improves hepatic abnormalities in male subjects
PMID: 26604653 2015 RCT (double-blind, placebo-controlled) n = 52
Finding: Treatment group showed statistically significant decreases in serum ALT and gamma-GTP and reduced urinary oxidative-stress markers vs placebo; authors concluded broccoli sprout extract is likely effective in improving liver function via reduction of oxidative stress. Small, short, single-population (Japanese males) biomarker-level trial.
Effect size: Significant reduction in ALT and gamma-GTP vs placebo (small trial)
View on PubMed
Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China
PMID: 16284385 2005 RCT (placebo-controlled) n = 200
Finding: No overall between-arm difference in aflatoxin-DNA adduct excretion, but inverse association between urinary dithiocarbamate (sulforaphane metabolite) levels and aflatoxin-DNA adducts, suggesting bioavailability-dependent reduction of a liver-carcinogen biomarker. Biomarker-level (hepatocarcinogen exposure) only; no liver-disease or liver-cancer-incidence endpoint.
Government Effect size: Inverse correlation of sulforaphane metabolite with aflatoxin-DNA adducts (subgroup/correlation)
View on PubMed
Effect of broccoli sprout extract and baseline gut microbiota on fasting blood glucose in prediabetes: a randomized, placebo-controlled trial
PMID: 39929977 2025 RCT (double-blind, placebo-controlled) n = 74
Finding: Primary endpoint not met overall (only ~0.2 mmol/L FBG reduction vs placebo); a microbiota-defined responder subgroup achieved ~0.4 mmol/L reduction. NO liver-specific outcomes reported. Included as metabolic-context evidence only; does not directly establish hepatic benefit.
Academic Effect size: FBG -0.2 mmol/L overall (NS-level), -0.4 mmol/L in responder subgroup
View on PubMed
KEAP1 and Done? Targeting the NRF2 Pathway with Sulforaphane
PMID: 29242678 2017 Narrative Review (mechanistic)
Finding: Establishes the NRF2-KEAP1 mechanistic basis for sulforaphane's hepatoprotective and detoxification activity (glutathione, NQO1, GST induction). Mechanistic anchor for liver-health rationale; does NOT itself establish human liver-disease clinical efficacy.
Academic Effect size: N/A (mechanistic review)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
Sulforaphane is not an approved drug and broccoli sprout / glucoraphanin products are marketed as dietary supplements; FDA has not evaluated them for the diagnosis, treatment, cure, or prevention of any disease. source↗
L4b EU EFSA
Neutral
1,548 claims on 'botanicals' have been placed on hold by the Commission pending further consideration on how to proceed with these source↗
L4d TW TFDA / 衛福部
Cautious
食品不得標示或廣告宣稱醫療效能 source↗
L5b Mayo Clinic
Cautious
L5c Cleveland Clinic
Cautious
L5d Harvard Health
Cautious
L5e Specialty Society (condition-mapped)
Cautious
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-liver-health-INT-sulforaphane-001 繁體中文版 →